Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
25.02
-0.38 (-1.48%)
Nov 5, 2024, 1:19 PM EST - Market open
Company Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.
Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity.
It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Celldex Therapeutics, Inc.
| Country | United States |
| Founded | 1983 |
| IPO Date | Mar 10, 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 160 |
| CEO | Anthony Marucci |
Contact Details
Address: Perryville III Building, Suite 220 Hampton, New Jersey 08827 United States | |
| Phone | 908 200 7500 |
| Website | celldex.com |
Stock Details
| Ticker Symbol | CLDX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000744218 |
| CUSIP Number | 15117B202 |
| ISIN Number | US15117B2025 |
| Employer ID | 13-3191702 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Anthony S. Marucci M.B.A. | Founder, President, Chief Executive Officer and Director |
| Dr. Tibor Keler Ph.D. | Founder, Chief Scientific Officer and Executive Vice President |
| Sam Martin | Senior Vice President, Chief Financial Officer, Secretary and Treasurer |
| Dr. Margo Heath-Chiozzi M.D. | Senior Vice President of Regulatory Affairs |
| Dr. Diane C. Young M.D. | Senior Vice President and Chief Medical Officer |
| Prof. Joseph P. Schlessinger Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Sarah Cavanaugh | Senior Vice President of Corporate Affairs and Administration |
| Freddy A. Jimenez Esq. | Senior Vice President and General Counsel |
| Dr. Ronald A. Pepin | Chief Business Officer and Senior Vice President |
| Elizabeth Crowley | Chief Product Development Officer and Senior Vice President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 8, 2024 | 10-Q | Quarterly Report |
| Aug 8, 2024 | 8-K | Current Report |
| Jun 14, 2024 | 144 | Filing |
| Jun 14, 2024 | 144 | Filing |
| Jun 14, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 14, 2024 | 8-K | Current Report |
| Jun 7, 2024 | 144 | Filing |
| Jun 7, 2024 | 144 | Filing |
| Jun 3, 2024 | 144 | Filing |
| Jun 3, 2024 | 144 | Filing |